21st.Bio submits EU application for precision-fermented dairy protein
The company is seeking access to Europe's dairy-protein market, where supplies of conventional whey protein face constraints. Its ingredient must undergo EU regulatory assessment before it can be sold in the region.
Beta-lactoglobulin, or BLG, is the principal protein in whey derived from milk. Food and nutrition manufacturers use it for its amino-acid composition and functional characteristics.
To manufacture the protein, 21st.Bio uses Aspergillus oryzae, a microorganism with a history of use in Japanese food fermentation. The underlying technology comes from a platform created by Novonesis. Under a licence, 21st.Bio has adapted that platform to manufacture alternative proteins at commercial scale.
A paper published in 2025 in the peer-reviewed journal Applied Microbiology and Biotechnology identified the strain's lineage as the first mycotoxin-free lineage of A. oryzae developed for industrial manufacture of alternative and novel proteins.
Alongside the filing, 21st.Bio has criticised the duration and complexity of the EU's Novel Food authorisation procedure. The company says uncertainty over approval schedules affects decisions about investment, manufacturing facilities and product launches.
21st.Bio is requesting a faster authorisation route for well-characterised proteins identical to those found in nature, made with established microbial strains and technologies whose safety records have been demonstrated. The company argues that greater regulatory predictability could encourage investment and commercialisation while preserving the EU's existing food-safety standards.




